DelveInsight reports that the Multiple Sclerosis (MS) pipeline includes over 75 key companies actively developing more than 80 therapeutic candidates.
Multiple sclerosis Overview:
Multiple sclerosis (MS) is the most common neurological disorder affecting young adults, typically emerging between the ages of 20 and 40. The disease targets the axons in the central nervous system, which are protected by myelin, often referred to as white matter.
The relapsing–remitting form of MS (RRMS) is the most prevalent, representing about 85% of cases. RRMS is characterized by periods of symptom flare-ups—known as relapses or exacerbations—followed by phases of partial or complete remission. Less common forms of MS present differently and less predictably. In RRMS, relapses may recur and are often triggered by specific factors.
Relapses involve either the sudden worsening of existing symptoms or the emergence of new symptoms lasting at least 24 hours, typically caused by new lesions or damage in the brain.
Early MS symptoms may include:
-
Visual disturbances: blurred or double vision, or optic neuritis causing eye pain and sudden vision loss
-
Muscle weakness: particularly in the arms or legs, often accompanied by stiffness and painful spasms
-
Sensory changes: tingling, numbness, or pain in the limbs, trunk, or face
-
Coordination and balance issues: clumsiness while walking
-
Bladder dysfunction
-
Dizziness: occasional or persistent
The severity and duration of these symptoms can vary widely among individuals.
Download our report @ https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Multiple sclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple sclerosis Therapeutics Market.
Key Takeaways from the Multiple sclerosis Pipeline Report
DelveInsight’s report on the Multiple Sclerosis (MS) pipeline highlights a dynamic landscape, with over 75 companies actively developing more than 80 therapeutic candidates.
Key regulatory updates include:
-
January 2025: The FDA issued a boxed warning for glatiramer acetate (Copaxone and its generics) due to rare but serious allergic reactions, including anaphylaxis. Patients are advised to seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling, or hives after an injection.
-
September 2024: The FDA approved a new device designed for short-term use to improve gait in MS patients with mild to moderate symptoms, providing a non-pharmacological option to aid mobility.
-
August 2024: The FDA approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab), for adults with relapsing forms of MS, aiming to increase treatment accessibility and potentially reduce costs.
Leading companies developing MS therapies include Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others.
Promising MS pipeline candidates in various stages of development include IMU-838, BIIB091, IMCY-0141, NeuroVax, among several additional therapies.
Multiple sclerosis Pipeline Analysis
The Multiple sclerosis pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Multiple sclerosis Market.
-
Categorizes Multiple sclerosis therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Multiple sclerosis drugs under development based on:
-
Stage of development
-
Multiple sclerosis Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Multiple sclerosis Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Multiple sclerosis Licensing agreements
-
Funding and investment activities supporting future Multiple sclerosis market advancement.
-
Request for a sample report @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Multiple sclerosis Emerging Drugs
-
IMU-838: Immunic Therapeutics
-
BIIB091: Biogen
-
IMCY-0141: ImCyse
-
NeuroVax: Immune Response BioPharma
Multiple sclerosis Companies
More than 75 leading companies are actively developing therapies for Multiple Sclerosis, with Immunic Therapeutics advancing a drug candidate to the most advanced stage—Phase III clinical trials.
DelveInsight’s report covers around 80+ products under different phases of Multiple sclerosis clinical trials like
-
Multiple sclerosis Late stage Therapies (Phase III)
-
Multiple sclerosis Mid-stage Therapies (Phase II)
-
Multiple sclerosis Early-stage Therapies (Phase I)
-
Multiple sclerosis Pre-clinical and Multiple sclerosis Discovery stage Therapies
-
Multiple sclerosis Discontinued & Inactive Therapies
Multiple sclerosis pipeline report provides the Multiple sclerosis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Multiple sclerosis Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Multiple sclerosis Therapies and Key Multiple sclerosis Companies: Multiple sclerosis Clinical Trials and recent advancements
Multiple sclerosis Pipeline Therapeutic Assessment
• Multiple sclerosis Assessment by Product Type
• Multiple sclerosis By Stage
• Multiple sclerosis Assessment by Route of Administration
• Multiple sclerosis Assessment by Molecule Type
Download Multiple sclerosis Sample report to know in detail about the Multiple sclerosis treatment market @ Multiple sclerosis Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Multiple sclerosis Current Treatment Patterns
4. Multiple sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple sclerosis Late-Stage Products (Phase-III)
7. Multiple sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple sclerosis Discontinued Products
13. Multiple sclerosis Product Profiles
14. Multiple sclerosis Key Companies
15. Multiple sclerosis Key Products
16. Dormant and Discontinued Products
17. Multiple sclerosis Unmet Needs
18. Multiple sclerosis Future Perspectives
19. Multiple sclerosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Multiple sclerosis Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
